<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet12788</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-12788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group></article-categories><title-group><article-title>Гиперкальциурия и гиперпаратиреоз – всегда ли есть связь?</article-title><trans-title-group xml:lang="en"><trans-title>Hypercalciuria and hyperparathyroidism — is there always a connection?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1341-0397</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирная</surname><given-names>C. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mirnaya</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мирная Светлана Сергеевна, кандидат медицинских наук</p><p>107076, Москва, ул. Короленко, д. 7-3-33</p><p>Scopus Author ID: 57191923409;</p><p>eLibrary SPIN: 1968-7706</p></bio><bio xml:lang="en"><p>Svetlana S. Mirnaya, MD, PhD</p><p>7-3-33 Korolenko street, 107076 Moscow</p><p>Scopus Author ID: 57191923409;</p><p>eLibrary SPIN: 1968-7706</p></bio><email xlink:type="simple">svetlanamirnaya@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6667-062X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремкина</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremkina</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Еремкина Анна Константиновна, кандидат медицинских наук</p><p>Москва</p><p>eLibrary SPIN: 8848-2660</p></bio><bio xml:lang="en"><p>Anna K. Eremkina, MD, PhD</p><p>Moscow</p><p>eLibrary SPIN: 8848-2660</p></bio><email xlink:type="simple">a.lipatenkova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ООО «Сеть семейных медицинских центров №1»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC «Set' semeinykh meditsinskikh tsentrov №1»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр эндокринологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>14</day><month>04</month><year>2022</year></pub-date><volume>19</volume><issue>1</issue><fpage>92</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мирная C.С., Еремкина А.К., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Мирная C.С., Еремкина А.К.</copyright-holder><copyright-holder xml:lang="en">Mirnaya S.S., Eremkina A.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/12788">https://www.omet-endojournals.ru/jour/article/view/12788</self-uri><abstract><p>Гиперкальциурия — это патологическое состояние, характеризующееся превышением суточной экскреции кальция. Высокая концентрация кальция в моче может инициировать камнеобразование. Различают несколько типов гиперкальциурии, каждый из которых требует индивидуального подхода. При отсутствии известных причин развития отдельно выделяют идиопатическую гиперкальциурию — частое дисметаболическое состояние, при котором наблюдается избыточная экскреция кальция с мочой в сочетании с нормокальциемией. Резорбтивная гиперкальциурия наиболее часто вызвана потерей кальция вследствие резорбции костной ткани при избытке паратгормона и развивается по причине первичного гиперпаратиреоза. Для дифференциальной диагностики между этими состояниями может применяться тиазидная проба. В данной статье приведен протокол пробы с гипотиазидом в амбулаторной практике, описана серия клинических случаев применения данной пробы. Установление диагноза представляется крайне важным для определения тактики дальнейшего наблюдения и лечения. Вторичный гиперпаратиреоз (повышение паратгормона в результате недостаточности витамина D, хронической почечной недостаточности или при других состояниях) требует медикаментозной коррекции, в то время как при подтверждении диагноза первичного гиперпаратиреоза обсуждается необходимость хирургического лечения. С учетом распространенности идиопатической гиперкальциурии и первичного гиперпаратиреоза целесообразно более широкое использование пробы с тиазидными диуретиками в клинической практике.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Hypercalciuria is a pathological condition characterized by an excess of daily calcium excretion. A high concentration of urine calcium can initiate stone formation. There are several types of hypercalciuria, each requires an individual approach. In the absence of known causes of development, idiopathic hypercalciuria is a frequent dysmetabolic disorder defined as an excess urine calcium excretion with normocalcemia. Resorptive hypercalciuria most often develops due to primary hyperparathyroidism and is caused by elevated PTH and excess release of calcium from bone stores. A thiazide test can be used for differential diagnosis between these conditions. We present a series of clinical cases covered the thiazide test in outpatient practice. The definitive diagnosis is extremely important because it determines the optimal treatment strategy. Secondary hyperparathyroidism (an increase in parathyroid hormone as a result of vitamin D deficiency, chronic renal failure or other conditions) requires medical therapy, while the primary hyperparathyroidism is radically cured only after surgical intervention.Taking into account the prevalence of idiopathic hypercalciuria and primary hyperparathyroidism, it is actual to use the thiazide test more widely in clinical practice.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперкальциурия</kwd><kwd>гиперпаратиреоз</kwd><kwd>первичный гиперпаратиреоз</kwd><kwd>вторичный гиперпаратиреоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypercalciuria</kwd><kwd>hyperparathyroidism</kwd><kwd>primary hyperparathyroidism</kwd><kwd>secondary hyperparathyroidism</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено при финансовой поддержке Министерства здравоохранения Российской Федерации в рамках выполнения государственного задания «Оптимизация Российского электронного реестра пациентов с первичным гиперпаратиреозом» № НИОКТР AAAA-A18-118051590060-2</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Голованов С.А., Сивков А.В., Анохин Н.В. Гиперкальциурия: принципы дифференциальной диагностики // Экспериментальная и клиническая урология. — 2015. — №4. — С. 86-92.</mixed-citation><mixed-citation xml:lang="en">Golovanov SA, Sivkov AV, Anohin NV. Hypercalciuria: principles of differential diagnostics. Experimental and clinical urology 2015;4:86-92. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lerolle N, Lantz B, Paillard F, et al. Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria. Am J Med. 2002;113(2):99-103. doi: https://doi.org/10.1016/s0002-9343(02)01152-x</mixed-citation><mixed-citation xml:lang="en">Lerolle N, Lantz B, Paillard F, et al. Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria. Am J Med. 2002;113(2):99-103. doi: https://doi.org/10.1016/s0002-9343(02)01152-x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-543. doi: https://doi.org/10.7326/0003-4819-158-7-201304020-00005</mixed-citation><mixed-citation xml:lang="en">Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-543. doi: https://doi.org/10.7326/0003-4819-158-7-201304020-00005</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ong GS, Walsh JP, Stuckey BG, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97(9):3138-3145. doi: https://doi.org/10.1210/jc.2012-1429</mixed-citation><mixed-citation xml:lang="en">Ong GS, Walsh JP, Stuckey BG, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97(9):3138-3145. doi: https://doi.org/10.1210/jc.2012-1429</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bollerslev J, Schalin-Jäntti C, Rejnmark L, et al. Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019;181(3):1-19. doi: https://doi.org/10.1530/EJE-19-0316</mixed-citation><mixed-citation xml:lang="en">Bollerslev J, Schalin-Jäntti C, Rejnmark L, et al. Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019;181(3):1-19. doi: https://doi.org/10.1530/EJE-19-0316</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li DF, Gao YL, Liu HC, et al. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis. J Transl Med. 2020;18(1):106. doi: https://doi.org/10.1186/s12967-020-02270-7</mixed-citation><mixed-citation xml:lang="en">Li DF, Gao YL, Liu HC, et al. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis. J Transl Med. 2020;18(1):106. doi: https://doi.org/10.1186/s12967-020-02270-7</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eisner BH, Ahn J, Stoller ML. Differentiating primary from secondary hyperparathyroidism in stone patients: the «thiazide challenge». J Endourol. 2009;23(2):191-192. doi: https://doi.org/10.1089/end.2008.0567</mixed-citation><mixed-citation xml:lang="en">Eisner BH, Ahn J, Stoller ML. Differentiating primary from secondary hyperparathyroidism in stone patients: the «thiazide challenge». J Endourol. 2009;23(2):191-192. doi: https://doi.org/10.1089/end.2008.0567</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Riss P, Kammer M, Selberherr A, et al. The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf ). 2016;85(2):196-201. doi: https://doi.org/10.1111/cen.13046</mixed-citation><mixed-citation xml:lang="en">Riss P, Kammer M, Selberherr A, et al. The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf ). 2016;85(2):196-201. doi: https://doi.org/10.1111/cen.13046</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017;102(4):1270-1276. doi: https://doi.org/10.1210/jc.2016-2481</mixed-citation><mixed-citation xml:lang="en">Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017;102(4):1270-1276. doi: https://doi.org/10.1210/jc.2016-2481</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
